Ishihara Aiko, Miyachi Takafumi, Nakamura Takeshi, Ohtsuki Toshiho, Kimura Yasuhiro, Kihira Kenji, Yamawaki Takemori, Matsumoto Masayasu
Department of Clinical Neuroscience and Therapeutics, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
Hiroshima J Med Sci. 2011 Sep;60(3):57-62.
The aim of this study is to clarify the relationship between serum 3-O-methyldopa (3-OMD) and the clinical effects of entacapone. The 3-OMD and maximum serum concentration (Cmax) of levodopa were measured in 21 Parkinson's Disease patients who took 100 mg levodopa / dopa decarboxylase inhibitor. After the administration of entacapone, the 3-OMD concentration and percentage of "on" time during waking hours (% of "on" time) were studied for 8 weeks. The 3-OMD concentration was reduced by 34%, and the increase in % of "on" time was 28% at the 8th week compared with baseline. We defined the COMT-index as [baseline 3-OMD concentration] / [levodopa Cmax when 100 mg levodopa was administered alone]. The COMT-index was significantly correlated with the increase in % of "on" time at the 8th week. In conclusion, the measurement of baseline 3-OMD and levodopa pharmacokinetics is useful for predicting the clinical effects of entacapone.
本研究的目的是阐明血清3 - O - 甲基多巴（3 - OMD）与恩他卡朋临床疗效之间的关系。在21例服用100mg左旋多巴/多巴脱羧酶抑制剂的帕金森病患者中测量了3 - OMD和左旋多巴的最大血清浓度（Cmax）。给予恩他卡朋后，对3 - OMD浓度和清醒时间“开”期百分比（“开”期百分比）进行了8周的研究。与基线相比，第8周时3 - OMD浓度降低了34%，“开”期百分比增加了28%。我们将儿茶酚 - O - 甲基转移酶指数（COMT指数）定义为[基线3 - OMD浓度]/[单独给予100mg左旋多巴时的左旋多巴Cmax]。COMT指数与第8周时“开”期百分比的增加显著相关。总之，测量基线3 - OMD和左旋多巴药代动力学有助于预测恩他卡朋的临床疗效。
